Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludrocortisone acetate tablets in salt-wasting congenital adrenal hyperplasia (CAH)
CTR20243531Phase 4Active
- Sponsor
- Hefei Future Drug Development
- Start
- Mar 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fludrocortisone in congenital adrenal hyperplasia (CAH), sponsored by Hefei Future Drug Development. Started Mar 2025; status: active.
02
Drugs
fludrocortisone
03
Conditions
congenital adrenal hyperplasia (CAH)
Beyond the preview
Go deeper on CTR20243531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243531.